Efficacy and Safety of Rifaximin in Treating MAFLD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of Rifaximin in Treating MAFLD — Stella

Recruiting

Back to Metabolic-associated Fatty Liver Disease trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Changzheng Hospital, Naval Medical University, shanghai, China, Shanghai, Shanghai Municipality

Key details

Phase

Very early testing

Sponsor

Shanghai Changzheng Hospital

Enrollment target

~40 participants

Started

August 2024

Primary completion

December 2027

Age range

18 Years – 75 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov